Patents by Inventor David B. Chang
David B. Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10363171Abstract: A process for performing retinal phototherapy or photostimulation includes generating a laser light that creates a therapeutic effect to retinal and/or foveal tissues exposed to the laser light without destroying or permanently damaging the retinal or foveal tissue. The laser light is applied to a first treatment area of the retina. After a predetermined interval of time, within a single treatment session, the laser light is reapplied to the first treatment area of the retina. During the interval of time between the laser light applications to the first treatment area, the laser light is applied to one or more additional areas of the retina that is spaced apart from the first treatment area and one another. The laser light is repeatedly applied to each of the areas to be treated until a predetermined number of laser light applications to each area to be treated has been achieved.Type: GrantFiled: May 6, 2016Date of Patent: July 30, 2019Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Patent number: 10357398Abstract: A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed laser beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature up to eleven degrees Celsius to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.Type: GrantFiled: November 15, 2017Date of Patent: July 23, 2019Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, David B. Chang, Benjamin W. L. Margolis
-
Patent number: 10307294Abstract: Providing neuroprotective therapy for glaucoma includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selected to create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and/or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and/or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and/or foveal tissue and improve function or condition of an optic nerve and/or retinal ganglion cells of the eye.Type: GrantFiled: March 29, 2018Date of Patent: June 4, 2019Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Patent number: 10299961Abstract: Providing neuroprotective therapy for glaucoma includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selected to create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and/or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and/or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and/or foveal tissue and improve function or condition of an optic nerve and/or retinal ganglion cells of the eye.Type: GrantFiled: April 25, 2018Date of Patent: May 28, 2019Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Publication number: 20190151676Abstract: A process for safely providing retinal phototherapy includes generating an interferometric signal or pattern by applying a near infrared light beam to a retinal pigment epithelium of a retina of an eye. A level or concentration of melanin within the retinal pigment epithelium of the retina is compared to a normal level or concentration using the detected interferometric signal or pattern. One or more treatment parameters of the retinal phototherapy is adjusted if the level or concentration of melanin in the retinal pigment epithelium of the eye exceeds the normal level or concentration by a predetermined amount.Type: ApplicationFiled: January 7, 2019Publication date: May 23, 2019Applicant: Ojai Retinal Technology, LLCInventors: David B. Chang, Jeffrey K. Luttrull
-
Publication number: 20190151151Abstract: A process for safely providing retinal phototherapy includes generating first and second light beams of a different wavelength. The first and second light beams are applied to a retinal pigment epithelium (RPE) and choroid of an eye. The amount of light reflected from the eye from the first light beam and the second light beam is measured, such as using a reflectometer. A level or concentration of the melanin within the eye is calculated using the measured amount of light reflected from the eye from the first and second light beams. When the content or density of melanin in the RPE exceeds a predetermined amount, one or more treatment parameters of the retinal phototherapy is adjusted.Type: ApplicationFiled: November 29, 2018Publication date: May 23, 2019Applicant: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, David B. Chang
-
Patent number: 10285859Abstract: A process for performing retinal phototherapy or photostimulation includes generating a laser light that creates a therapeutic effect to retinal and/or foveal tissues exposed to the laser light without destroying or permanently damaging the retinal or foveal tissue. The laser light is applied to a first treatment area of the retina. After a predetermined interval of time, within a single treatment session, the laser light is reapplied to the first treatment area of the retina. During the interval of time between the laser light applications to the first treatment area, the laser light is applied to one or more additional areas of the retina that is spaced apart from the first treatment area and one another. The laser light is repeatedly applied to each of the areas to be treated until a predetermined number of laser light applications to each area to be treated has been achieved.Type: GrantFiled: October 12, 2016Date of Patent: May 14, 2019Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Patent number: 10278863Abstract: A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed laser beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature up to eleven degrees Celsius to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.Type: GrantFiled: June 21, 2017Date of Patent: May 7, 2019Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, David B. Chang, Benjamin W. L. Margolis
-
Patent number: 10278865Abstract: Providing neuroprotective therapy for glaucoma includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selected to create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and/or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and/or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and/or foveal tissue and improve function or condition of an optic nerve and/or retinal ganglion cells of the eye.Type: GrantFiled: May 3, 2018Date of Patent: May 7, 2019Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Patent number: 10194798Abstract: A process for determining levels or concentrations of melanin within an eye includes generating first and second light beams of a different wavelength. The first and second light beams are applied into the eye, such as a retinal pigment epithelium and choroid of the eye. The amount of light reflected from the eye from the first light beam and the second light beam is measured, such as using a reflectometer. A level or concentration of the melanin within the eye is calculated using the measured amount of light reflected from the eye from the first and second light beams.Type: GrantFiled: November 20, 2017Date of Patent: February 5, 2019Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, David B. Chang
-
Publication number: 20180339167Abstract: A process for heat treating biological tissue includes providing a plurality of energy emitters formed into an array. Treatment energy is generated from the plurality of emitters and applied to target tissue. The treatment energy has energy and application parameters selected so as to raise the target tissue temperature sufficiently to create a therapeutic effect while maintaining an average temperature of the target tissue over several minutes at or below a predetermined temperature so as not to destroy or permanently damage the target tissue.Type: ApplicationFiled: July 19, 2018Publication date: November 29, 2018Applicant: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, David B. Chang, Benjamin W. L. Margolis
-
Publication number: 20180339170Abstract: A process for heat treating biological tissue includes generating treatment radiation having a predetermined wavelength and average power. The treatment radiation is applied to biological tissue, such as retinal tissue, such that at least one treatment spot is formed on the biological tissue and the biological tissue is heat stimulated sufficiently to create a therapeutic effect without destroying the tissue.Type: ApplicationFiled: July 18, 2018Publication date: November 29, 2018Applicant: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, David B. Chang, Benjamin W. L. Margolis
-
Patent number: 10117777Abstract: Providing neuroprotective therapy for glaucoma includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selected to create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and/or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and/or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and/or foveal tissue and improve function or condition of an optic nerve and/or retinal ganglion cells of the eye.Type: GrantFiled: October 24, 2016Date of Patent: November 6, 2018Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Publication number: 20180280196Abstract: Providing neuroprotective therapy for glaucoma includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selected to create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and/or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and/or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and/or foveal tissue and improve function or condition of an optic nerve and/or retinal ganglion cells of the eye.Type: ApplicationFiled: April 25, 2018Publication date: October 4, 2018Applicant: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Publication number: 20180271707Abstract: Providing neuroprotective therapy for glaucoma includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selected to create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and/or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and/or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and/or foveal tissue and improve function or condition of an optic nerve and/or retinal ganglion cells of the eye.Type: ApplicationFiled: May 3, 2018Publication date: September 27, 2018Applicant: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Publication number: 20180221206Abstract: Providing neuroprotective therapy for glaucoma includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selected to create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and/or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and/or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and/or foveal tissue and improve function or condition of an optic nerve and/or retinal ganglion cells of the eye.Type: ApplicationFiled: March 29, 2018Publication date: August 9, 2018Applicant: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Publication number: 20180200532Abstract: A process for heat treating biological tissue includes repeatedly applying a pulsed energy to a target tissue over a period of time so as to controllably raise a temperature of the target tissue to create a therapeutic effect to the target tissue without destroying or permanently damaging the target tissue. After the first treatment is concluded the application of the pulsed energy to the target tissue is halted for an interval of time. Within a single treatment session a second treatment is performed on the target tissue after the interval of time by repeatedly reapplying the pulsed energy to the target tissue so as to controllably raise the temperature of the target tissue to therapeutically treat the target tissue without destroying or permanently damaging the target tissue.Type: ApplicationFiled: March 12, 2018Publication date: July 19, 2018Applicant: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, David B. Chang, Benjamin W. L. Margolis
-
Patent number: 9962291Abstract: Providing neuroprotective therapy for glaucoma includes generating a micropulsed laser light beam having parameters and characteristics, including pulse length, power, and duty cycle, selected to create a therapeutic effect with no visible laser lesions or tissue damage to the retina. The laser light beam is applied to retinal and/or foveal tissue of an eye having glaucoma or a risk of glaucoma to create a therapeutic effect to the retinal and/or foveal tissue exposed to the laser light beam without destroying or permanently damaging the retinal and/or foveal tissue and improve function or condition of an optic nerve and/or retinal ganglion cells of the eye.Type: GrantFiled: August 9, 2016Date of Patent: May 8, 2018Assignee: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, Benjamin W. L. Margolis, David B. Chang
-
Publication number: 20180078412Abstract: A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed laser beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature up to eleven degrees Celsius to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.Type: ApplicationFiled: November 15, 2017Publication date: March 22, 2018Applicant: Ojai Retinal Technology, LLCInventors: Jeffrey K. Luttrull, David B. Chang, Benjamin W. L. Margolis
-
Publication number: 20170319383Abstract: A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed laser beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature up to eleven degrees Celsius to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.Type: ApplicationFiled: June 21, 2017Publication date: November 9, 2017Inventors: Jeffrey K. Luttrull, David B. Chang, Benjamin W. L. Margolis